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The role of pharmacogenetics  
in keloid scar treatment:  
A literature review
Tamara Searle1, Faisal R Ali2 and Firas Al-Niaimi2,3
Abstract
Background: The pathophysiology of keloid scars is still not fully understood and a universally reliable effective 
treatment has not been identified. Pharmacogenetics explores how drug response to a particular therapy can 
relate to genetic variations.
Purpose: To investigate how pharmacogenetics could be applied to keloid scars and the relevance of this to 
clinical practice.
Methods: We reviewed the literature and discuss our current knowledge of pharmacogenomics in the treatment 
of keloid scars. A literature search was performed using the terms ‘Pharmacogenetics’, ‘Pharmacogenomics’, 
‘Keloid’ and ‘Scar’. We searched the PubMed, MEDLINE and EMBASE databases to find the relevant articles. 
Only articles in English were chosen. The level of evidence was evaluated and selected accordingly listing the 
studies with the highest level of evidence first.
Results: Treatments including corticosteroid injections and 5-fluorouracil can be effective in some patients, 
but less so in others. Polymorphisms of the glucocorticoid receptor and variants of CCL2, YAP1, miR-21-5p and 
NF-κβ might be responsible for different responses to treatments used in keloid scars such as 5-fluorouracil. 
Small molecule inhibitors might be utilised to target other implicated genes.
Conclusion: Pharmacogenetics aims to produce the most efficacious patient outcomes while reducing adverse 
effects. Understanding the pharmacogenetics of keloid scars could lead to a new era of personalised medicine 
in the treatment of keloid scars. At present, there is some evidence (level 3b/4) to suggest genetic variations 
that are responsible to drug response in keloids, but further research in this field is required.
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Introduction
Pharmacogenetics is the discipline that explores 
whether a genetic variation can predict drug 
therapy response.1,2 This has been applied in 
aspects of medicine including targeted treat-
ments in oncology.3 It has also been used for pre-
dictive assessment of those at risk of adverse drug 
reactions, such as thiopurine methyltransferase 
(TPMT) deficiency—secondary to TPMT gene 
defect—predisposing to agranulocytosis in thio-
purine drugs.4
Keloid scars are fibro-proliferative lesions 
manifesting as disfiguring, protuberant scars 
extending beyond the bounds of the original 
trauma.5 Typical sites include the earlobes, shoul-
ders and sternum. While there is a recognition 
that certain ethnic groups are predisposed to 
keloid scars (higher Fitzpatrick skin types), the 
precise pathophysiology has not been fully eluci-
dated. Genome-wide association studies (GWAS) 
have allowed for identification of several genetic 
loci in families of different ethnicities such as 
African Americans who are susceptible to devel-
oping keloid scars.6 Substantial evidence impli-
cates mechanobiological factors such as pressure 
and tension in the pathogenesis and sustainment 
of keloids. These factors exert changes at intra-
cellular and extracellular levels with signalling 
pathways involved in scar formation and fibrosis. 
Histological analysis has also shown increased 
angiogenesis and inflammation at sites of high 
tension such as the keloid edges.7
A broad range of therapies are used for patients 
with keloid scars, none of which are universally suc-
cessful. Non-invasive treatments tend to suppress 
fibroblast proliferation rate and genesis of extra-
cellular matrix and collagen.5 They also induce 
apoptosis and suppress inflammation and upregu-
late matrix metalloproteinase to prevent keloid 
scar formation.5 Non-invasive therapies include 
pressure garment therapy, silicon gel sheeting, 
onion extract and heparin gel, intralesional corti-
costeroid and 5-fluorouracil (5-FU) injections, 
bleomycin and mitomycin C.5 Corticosteroid ther-
apy remains the mainstay of treatment.8
Surgical excision can be used with a reduc-
tion in relapse rates achieved when combined 
with adjunctive steroid treatment.9 Combination 
of surgery followed by radiation and corticoster-
oid tape was found to be most efficacious for 
maintaining long-term disease control and sup-
pression of regrowth.10
Lasers have shown to play a role in the man-
agement of keloids, albeit limited, and are most 
effective in combination with corticosteroids.11
More recently, pharmacogenetic studies have 
investigated differing treatment response among 
patients. There is a paucity of literature investigat-
ing pharmacogenetics of keloid scars and how 
treatment response can be influenced by pharma-
cogenetics. Our review addresses these apparent 
gaps in the literature and supports the need for 
personalised medicine in the treatment of keloid 
scars. The aim of the present study was to review 
the pharmacogenetics and investigate how per-
sonalised and targeted medications could be used 
for improved clinical outcomes in keloid scars.
Methods
Using the keywords ‘Pharmacogenetics’, 
‘Pharmacogenomics’, ‘Keloid’ and ‘Scar’, we 
searched the PubMed, MEDLINE and EMBASE 
databases to find the relevant literature in English 
language articles only. Our review was conducted 
in June 2020 and the time period of evidence was 
collected from the inception of these databases 
till 16 June 2020.The level of evidence was evalu-
ated and selected according to the highest level 
and working our way downwards. Using the 
Oxford Centre of Evidence-Based Medicine 2011 
guidance, we analysed and listed the evidence 
based on its strength from level 1 to level 5 with 
systematic reviews and meta-analyses considered 
first, randomised controlled trials second, cascad-
ing down to weaker evidence such as case reports.
Lay summary
The varied response to similar therapeutic treatments in keloids has prompted the consideration of 
the role of genetic variants on response in the form of pharmacogenetics. Pharmacogenetics refers to 
drugs and their metabolism and action based on genetic influences. The ideal scenario would involve 
the selection of treatment based on the individual’s specific genetic variants to ensure maximum efficacy 
with minimal toxicity. Some evidence currently points to genetic variations in some keloid patients that 
might be of relevance to the treating clinician.
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Pharmacogenetics and keloids
Pharmacogenetics is used in reference to genes 
and their relation to drug metabolism,12 whereas 
pharmacogenomics refers to all genes in the 
genome that may determine the drug response.13 
Pharmacogenetics explores single genes and their 
effect on the action of drugs, while pharmacog-
enomics studies many genes and their patterns 
alone and in combination. Pharmacogenomics 
therefore acknowledges that the response to a 
drug may be multifactorial.12
GWAS are used to discover whether single 
nucleotide polymorphisms (SNP) may be associ-
ated with a particular phenotype such as the 
response to a particular medication.14
In addition to the DNA coding section for 
proteins (genes), increasing evidence highlights 
the role of non-coding sections of DNA playing a 
role or be associated with a particular phenotype. 
Epigenetics involves heritable DNA gene func-
tion and expression changes without modifying 
the gene DNA sequence. Epigenetic mechanisms 
reported include histone and covalent DNA 
modification and regulation of non-coding RNA 
and DNA methylation15 with different gene 
expression altering patterns of DNA methylation 
and histone modification.16 This process of epi-
genetics affects not only cell phenotypes, but also 
the heterogeneity in drug response. Newer drugs 
have been designed to regulate epigenetic pro-
cesses in disease states, further developing the 
notion of personalised medicine.17
Identifying patients likely to 
respond to treatments
Some keloid scars appear sporadic, but others 
are likely to represent a familial genetic disease 
in which multiple genetic mutations each confer 
varying degrees of predisposition to keloid 
scar development.18 Mendelian inheritance is 
described in keloid-associated syndromes such as 
Rubinstein-Taybi, Goeminne syndrome, lateral 
meningocele, Leigh necrotising encephalomye-
lopathy, Ullrich congenital muscular dystrophy 
and Ehlers-Danlos syndrome. These all have a 
dominant inheritance pattern in common.18,19
Linkage and GWAS studies have found asso-
ciations on chromosomes 2q23 and 7p11 in 
Japanese and African American families, respec-
tively (Table 1).18 Two possible susceptibility loci 
found in a Chinese Han family were 18q21.1 and 
10q23.31.20 In a GWAS involving Japanese 
patients, three susceptibility loci were found. 
These were 1q41, 3q22.3-23 and 15q21.3.21
The role of pharmacogenetics and the varied 
response to treatments has been studied with 
5-FU and glucocorticoids in the treatment of 
keloids.
Results
The results of this review are summarised in 
Table 2.
Corticosteroids
Glucocorticoids are most commonly used as 
first-line treatment for keloid scars with varia-
ble responses and relapse rates. In a study 
involving 19 patients (later categorised as 12 
steroid-responsive and seven steroid-non-
responsive), intralesional glucocorticoids were 
injected in keloids and their response moni-
tored over four weeks.22 Response was quanti-
fied using full-field laser perfusion imaging, 
spectrophotometric intracutaneous analysis of 
collagen and melanin, immunohistochemical 
studies, in addition to clinical response. 
Histological methods assessed alterations in 
epidermal thickness and glycosaminoglycan 
expression. Reverse transcriptase polymerase 
chain reactions (PCR), immunoblotting and 
Table 1. Implicated chromosomes and variants for keloid susceptibility and 5-FU response.
Susceptible ethnicities Chinese Han Possible implicated chromosomes
18q21.1 and 10q23.31
 Japanese 2q23 and 7p11 (susceptible loci 1q41, 
3q22.3-23 and 15q21.3)
 African American 2q23 and 7p11
Implicated variants possibly affecting 
5-FU Response
CCL2, YAP1, miR-21-5p, NF- κβ  
5-FU, 5-fluorouracil.
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immunohistochemistry were used to examine 
changes in expression of the glucocorticoid 
receptor in keloid tissues.22
At week 4, responders had a significant 
decrease in levels of melanin (0.43 [range = 0.32–
0.50] compared to a baseline value of 147.7 meas-
ured with spectrophotometric intracutaneous 
analysis SIAscopy, P = 0.002), glycosaminoglycan 
(0.90 [range = 0.871–0.92] compared to 
a baseline of 11130, P = 0.013), epidermal thick-
ness (0.74 = 0.57–0.83] compared to a baseline of 
766.2, P = 0.015) and reduced perfusion 
(P < 0.001) compared with non-responders. The 
decreased melanin content observed in some 
dark-skinned individuals after glucocorticoid treat-
ment might relate to mechanisms of pharmacoge- 
netics. The authors speculate that darker-skinned 
individuals experience glucocorticoid inhibition 
of melanogenesis through apprehension of the 
melanocyte cell cycle.22 This is consistent with 
the fact that darker-skinned individuals exhibit 
greater hypopigmentation in response to steroid 
treatment,23,24 possibly, related to the size gradient 
of melanosomes with the largest found melano-
somes in keratinocytes found in dark skin, followed 
by Asian and then Caucasian skin.24 It is still unclear 
whether the level of hypopigmentation relates to 
the effects of corticosteroids or a combination of 
this and the above mentioned effects.
Glucocorticoid receptor (GR; encoded by 
gene NR3C1) expression in steroid responders 
was significantly greater than non-responders at 
baseline. In steroid-responders, GR expression 
decreased, as measured by mRNA and protein 
Table 2. Results of pharmacogenetic studies.
Study author Year Intervention Outcome
Glucocorticoids
Rutkowski et al.22 2015 Intralesional 
glucocorticoids 
injected
At week 4, responders had a significant decrease in levels of 
melanin 0.43 compared to a baseline value of 147.7 (P = 0.002), 
glycosaminoglycan (0.90 [95% CI = 0.871–0.92] compared to a baseline 
of 11130, P = 0.013), epidermal thickness (0.74 [95% CI = 0.57–0.83] 
compared to a baseline of 766.2, P = 0.015) and reduced perfusion (P < 
0.001) compared with non-responders.
5-FU
LaRanger et al.28 2019 Keloids treated 
with 5-FU
Suppression of YAP1 gene and upregulation of CCL20 was observed in 
those areas that had been responsive to treatment.
New candidates
Leng et al.33 2005 N/A The expression of TRAIL-R2/DR5 in fibroblasts of hyperplastic scars was 
significantly decreased compared with healthy tissues.
Liu et al.35 2014 N/A MicroRNAs levels were significantly higher in keloid fibroblast tissues 
compared with healthy tissues, supporting its role in cell proliferation 
via targeting of PTEN. PTEN was low in keloid tissues compared with 
normal skin tissues.
Wu et al.37 2014 Keloid fibroblast 
cells were 
transfected with 
microRNA-199a-5p
Keloid fibroblast cells transfected with microRNA-199a-5p had 
decreased cell proliferation, and an altered cell cycle compared with 
healthy skin cells transfected with microRNA-199a-5p.
Syed et al.39 2011 N/A A significant increase in collagen types I and III mRNA were found in the 
perilesional areas of keloid scars as compared with extralesional and 
intralesional sites in both in vivo and in vitro samples.
Makino et al.41 2008 A novel NF-κβ 
inhibitor DHMEQ 
was used in keloid 
treatment.
DHMEQ markedly attenuated cell proliferation and reduced type 1 
collagen levels in keloid fibroblasts.
5-FU, 5-fluorouracil; CI, confidence interval; DHMEQ, dehydroxymethylepoxyguinomicin.
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expression (gauged by reverse transcriptase-PCR 
and western blotting) after glucocorticoid treat-
ment. It is thought that glucocorticoids are 
responsible for the downregulation of GR in cells 
and tissue.25 Keloid responsiveness to glucocorti-
coids is thought to therefore be related to baseline 
glucocorticoid receptor levels and downregula-
tion of these glucocorticoid receptors.22
An alternative isoform of GR, GR-β, inhibits 
GR-facilitated expression.26 GR-β could be 
responsible for reduced GR expression in non-
responders and the absence of GR downregula-
tion after glucocorticoid treatment.27
5-Fluorouracil
The gene expression of keloid scars treated with 
5-FU was analysed in a study by LaRanger et al.28 
The microarray results from treated and untreated 
areas of keloid scars were investigated. Using 
Random Forest analysis, distinct expression pro-
files were found in the treated and untreated 
areas. Random Forest analysis is a type of machine-
learning algorithm that can carry out thousands 
of rounds of gene analysis on global gene expres-
sion arrays to increase statistical power. Using this 
method enabled thousands of gene analytics to 
be produced to create an extrapolative gene 
expression profile with fewer false positives. This 
was visualised through multidimensional analysis 
and a selection of genes most likely to influence 
keloid treatment was suggested. In keloids treated 
with 5-FU, suppression of YAP1 gene and upregu-
lation of CCL20 was observed in those areas that 
had been responsive to treatment.28 YAP1 gene is 
thought to have pro-fibrotic capabilities involved 
in the positive feedback loop that augments and 
maintains fibrosis.29 CCL-2 is a regulator of T cell 
activity downstream of TGF-ß.
No changes in genes previously associated 
with keloids were found in the study by LaRanger 
et  al.28 For example, no changes in the genes 
coding for TGF-β, PDGF, MMPs, IL-1, IL-6 and 
IL-10 were found. These proinflammatory 
cytokines have previously been associated with 
fibroinflammatory disease.30,31 In addition, gene 
networks were disrupted, such as the IL-17A 
pathway.28
New candidates
The formation of keloid scars could be related to 
the imbalance of fibroblast apoptosis of scar tis-
sue and tumour necrosis factor related apoptosis 
inducing ligand (TRAIL) of fibroblasts.32 TRAIL 
is thought to bind to its receptor, acting as an 
intermediary in fibroblast apoptosis.32 The inves-
tigation of TRAIL and TRAIL-R2/death receptor 
5 (DR5) for treating keloids has been reviewed.32 
The expression of TRAIL-R2/DR5 in fibroblasts 
of hyperplastic scars has been found to be signifi-
cantly decreased compared with healthy tissues 
leading to the lack of apoptosis and uncontrolled 
fibroblast activation.33
MicroRNAs are non-coding RNAs that play a 
role in the regulation of gene expression.34 
MicroRNAs levels were significantly higher in 
keloid fibroblast tissues compared with healthy 
tissues, possibly supporting its role in cell prolif-
eration via targeting of phosphatase and tensin 
homolog deleted on chromosome 10 (PTEN).35 
PTEN has been found to inhibit cell prolifera-
tion, survival and growth36 and was low in keloid 
tissues compared with normal skin tissues.35 The 
present study highlighted the possible associa-
tions between microRNA-21 expression, keloid 
fibroblast apoptosis and cell proliferation.
Conversely, other microarray analysis studies 
utilising PCR methods found decreased micro-
RNA-199a-5p expression in keloid tissues com-
pared with normal tissue. Keloid fibroblast cells 
which were transfected with this particular micro-
RNA-199a-5p had decreased cell proliferation 
and an altered cell cycle (longer S and G2/M 
stages)37 compared with healthy skin cells trans-
fected with microRNA-199a-5p. The latter, there-
fore, might play a fundamental part in inhibiting 
keloid fibroblast proliferation.38
A significant increase in collagen types I and 
III mRNA were found in the perilesional areas of 
keloid scars as compared with extralesional and 
intralesional sites in both in vivo and in vitro 
samples.39 This suggests that keloid fibroblasts 
may have heterogeneous activity levels in vitro 
and in different parts of the keloid. The present 
study suggests heterogeneity of cellular function 
and by implication heterogeneity of response to 
therapy.30
The NF-κβ pathway has been implicated in the 
keloid fibroblasts activation.40 Proinflammatory 
cytokines such as interleukin-1 and tumour necro-
sis factor-α are activated by NF-κβ in a positive 
feedback mechanism. A novel NF-κβ inhibitor 
dehydroxymethylepoxyquinomicin (DHMEQ) 
was trialled in keloid treatment.41 Baseline NF-κβ 
was inherently raised in keloid fibroblast cells, sup-
porting the concept that the NF-κβ pathway is fun-
damental for keloid pathogenesis. DHMEQ 
markedly attenuated cell proliferation and 
reduced type 1 collagen levels in keloid fibroblasts. 
Therefore, patients who have NF-κβ elevations 
could benefit from such therapy.41
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Discussion
Responsiveness to glucocorticoids in keloid 
patients is likely to be related to the baseline GR 
level and possibly a lack of GR-β isoform. 
Screening for the presence of GR and related iso-
forms could, perhaps, prevent ineffective gluco-
corticoid treatment and the numerous adverse 
effects associated with repeated futile treatments 
in patients who do not appear to respond to ini-
tial corticosteroid treatment.22
In terms of 5-FU, our findings suggest that 
YAP1 gene and CCL2 genes are candidates for 
further analysis and studies investigating 
whether their possession and activity confers 
greater likelihood of response of keloids to 5-FU 
are warranted.28,29 CCL2 has also been impli-
cated in multiple sclerosis.31 Patients with multi-
ple sclerosis treated with methylprednisolone 
after a relapse were found to have a significant 
decrease in CCL2 serum levels after five days of 
treatment with a decrease from 268.35 ± 132.7 
to 129.8 ± 50.95 in the serum levels of CCL2  
(P = 0.045) (values compared with CCL2 stand-
ards). Clinical improvement in patients with 
multiple sclerosis treated with methylpredniso-
lone after a relapse could be associated with 
immediate decrease in CCL2 levels.31
For new treatment candidates, the use of DR5 
agonists (such as conatumumab, drozitumab, 
lexatumumab and tigatuzumab) has been sug-
gested in order to upregulate TRAIL-R2/DR5 and 
reduce the formation of keloid scars through ini-
tiation of apoptosis.32 This requires further investi-
gation and the risk of hepatotoxicity associated 
with these medications cannot be overlooked.42
Further studies are required to elucidate the 
exact mechanism of microRNA-199a-5p in keloid 
pathogenesis. Recently, miR-21-5p inhibitors 
were shown to reduce keloid fibroblast auto-
phagocytosis. This was associated with a decrease 
in expression of miR-21-5p and an increase in 
expression of apoptosis-associated genes. These 
laboratory findings have not yet been translated 
into clinical practice. Nevertheless, they suggest 
that miR-21-5p might be a useful therapeutic tar-
get to reduce keloid recurrence.39
The strengths of this review include the wide 
search parameters employed and the depth of lit-
erature investigated implicating several gene loci 
associated with pharmacogenetics in keloid scars. 
This review is limited by the small number of 
clinical studies investigating this field of research 
as well as the lack of inclusion of non-English lan-
guage articles. Future research will hopefully 
expand reviews such as this one, enabling better 
understanding of an interesting and important 
field of dermatology.
In the present article, we have recommended 
screening patients with keloids for certain genetic 
loci. This could revolutionise treatment for 
patients but is likely to be impractical and unfea-
sible for current clinical practice in healthcare 
systems evaluating cost-effectiveness. In the 
future, we envisage keloid management to be 
handled with a personalised approach. Increasing 
understanding of the pharmacogenetics of keloid 
scars will hopefully lay the foundations for future 
treatment in which keloid treatment is managed. 
Targeted therapies of particular gene loci in sus-
ceptible individuals could improve patient out-
comes and their quality of life.
Conclusion
Keloid scars are likely to represent complex 
genetic diseases with a number of genes each 
imparting susceptibility to keloid scars. Initial 
studies have suggested that screening for poly-
morphisms of the glucocorticoid receptor may 
indicate responsiveness to corticosteroids and 
variants of CCL2, YAP1, miR-21-5p and NF-κβ 
may indicate response to 5-FU. There are addi-
tional genes that could be targeted with small 
molecule inhibitors. Identifying these loci and 
further investigation of pharmacogenetics could 
allow for targeted and personalised treatments of 
keloid scars.43
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